Cellectar Biosciences Announces 2024 Annual Meeting of Stockholders on June 14
Ticker: CLRB · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | DEF 14A |
| Filed Date | Apr 26, 2024 |
| Risk Level | |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.00001, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Stock Incentive Plan, Executive Compensation, Auditor Ratification
TL;DR
<b>Cellectar Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to vote on director elections, stock incentive plan amendments, auditor ratification, and executive compensation.</b>
AI Summary
Cellectar Biosciences, Inc. (CLRB) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting to be held virtually on June 14, 2024, at 10:00 AM local time. Key agenda items include election of two Class I directors. Proposal to increase shares available under the 2021 Stock Incentive Plan by 7,000,000. Ratification of Baker Tilly US, LLP as independent registered public accounting firm for FY2024. Non-binding advisory vote on named executive officer compensation.
Why It Matters
For investors and stakeholders tracking Cellectar Biosciences, Inc., this filing contains several important signals. Stockholders will vote on increasing the number of shares available under the 2021 Stock Incentive Plan by 7,000,000, which could impact future equity compensation and dilution. The meeting includes a non-binding advisory vote on executive compensation, allowing shareholders to voice their opinions on the pay packages for named executive officers.
Risk Assessment
Risk Level: — Cellectar Biosciences, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate a change in risk.
Analyst Insight
Stockholders should review the proposals, particularly the stock incentive plan increase and executive compensation, before voting at the June 14th Annual Meeting.
Key Numbers
- 7,000,000 — Shares to be added (Under the 2021 Stock Incentive Plan)
- June 14, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
- April 24, 2024 — Record Date (Stockholders of record on this date are entitled to vote)
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of Annual Meeting
- Baker Tilly US, LLP (company) — Independent registered public accounting firm
- 2021 Stock Incentive Plan (plan) — Plan for which shares will be increased
- April 24, 2024 (date) — Record date for voting eligibility
FAQ
When did Cellectar Biosciences, Inc. file this DEF 14A?
Cellectar Biosciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Cellectar Biosciences, Inc. (CLRB).
Where can I read the original DEF 14A filing from Cellectar Biosciences, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cellectar Biosciences, Inc..
What are the key takeaways from Cellectar Biosciences, Inc.'s DEF 14A?
Cellectar Biosciences, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: Annual Meeting to be held virtually on June 14, 2024, at 10:00 AM local time.. Key agenda items include election of two Class I directors.. Proposal to increase shares available under the 2021 Stock Incentive Plan by 7,000,000..
Is Cellectar Biosciences, Inc. a risky investment based on this filing?
Based on this DEF 14A, Cellectar Biosciences, Inc. presents a moderate-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate a change in risk.
What should investors do after reading Cellectar Biosciences, Inc.'s DEF 14A?
Stockholders should review the proposals, particularly the stock incentive plan increase and executive compensation, before voting at the June 14th Annual Meeting. The overall sentiment from this filing is neutral.
How does Cellectar Biosciences, Inc. compare to its industry peers?
Cellectar Biosciences operates in the pharmaceutical preparations industry, focusing on developing and commercializing targeted therapies.
Are there regulatory concerns for Cellectar Biosciences, Inc.?
The filing is a proxy statement (DEF 14A) filed under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
Industry Context
Cellectar Biosciences operates in the pharmaceutical preparations industry, focusing on developing and commercializing targeted therapies.
Regulatory Implications
The filing is a proxy statement (DEF 14A) filed under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
What Investors Should Do
- Review the proposals for the 2024 Annual Meeting, including director nominees and the stock incentive plan amendment.
- Evaluate the rationale for the proposed increase in shares for the 2021 Stock Incentive Plan.
- Consider the advisory vote on named executive officer compensation and cast your vote accordingly.
Key Dates
- 2024-06-14: 2024 Annual Meeting of Stockholders — To vote on director elections, stock incentive plan, auditor ratification, and executive compensation.
- 2024-04-24: Record Date — Stockholders of record on this date are entitled to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, which is a standard procedural document and does not represent a change from previous filings in terms of financial or operational performance.
Filing Stats: 4,745 words · 19 min read · ~16 pages · Grade level 12 · Accepted 2024-04-26 16:58:41
Key Financial Figures
- $0.00001 — 35,848,924 shares of our common stock, $0.00001 par value per share, 237.5 shares of Se
- $0.0001 — tible Voting Preferred Stock, par value $0.0001 per share ( “Series E-2 Preferred
Filing Documents
- tm2412804d1_def14a.htm (DEF 14A) — 517KB
- tm2412804d1_def14a001.jpg (GRAPHIC) — 178KB
- tm2412804d1_def14a002.jpg (GRAPHIC) — 205KB
- tm2412804d1_def14aimg001.jpg (GRAPHIC) — 192KB
- tm2412804d1_def14aimg002.jpg (GRAPHIC) — 207KB
- tm2412804d1_def14aimg01.jpg (GRAPHIC) — 1KB
- 0001104659-24-053057.txt ( ) — 1598KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 26 COMPENSATION OF EXECUTIVE OFFICERS AND DIRECTORS 28
Executive Compensation
Executive Compensation 28 Equity Awards 28 Employment Agreements 29 2023 Outstanding Equity Awards at Fiscal Year-End 29 Risks Related to Compensation Policies and Practices 30 Pay Versus Performance 30 2023 Director Compensation 33 EQUITY COMPENSATION PLAN INFORMATION 33 WHERE YOU CAN FIND MORE INFORMATION 34 FORM 10-K 34 APPENDIX A CELLECTAR BIOSCIENCES, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED A-1 iv Cellectar Biosciences, Inc. PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS To be held on June 14, 2024 GENERAL INFORMATION This proxy statement is furnished to the stockholders of Cellectar Biosciences, Inc. (the “Company”, “Cellectar”, “we”, “us”, “our”) in connection with the solicitation of proxies by and on behalf of the Board of Directors of the Company (the “Board of Directors” or the “Board”) for use at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on June 14, 2024 at 10:00 A.M., local time, and at any adjournment or adjournments thereof. We will hold the Annual Meeting as a virtual meeting held entirely over the Internet. You will be able to attend the Annual Meeting, vote your shares electronically and submit your questions online by visiting www.virtualshareholdermeeting.com/CLRB2024 and entering the 16-digit control number included in your Notice of Internet Availability of Proxy Materials (the “Notice”), your proxy card, or the voting instructions that accompanied these proxy materials. We believe that conducting the Annual Meeting as a virtual meeting will encourage higher levels of stockholder participation. As permitted by the rules of the SEC, we are making this proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, available to our stockholders electronically via the Internet at www.proxyvote.com. On or about April 26, 2024, we mailed to